Crispr Therapeutics' stock soars premarket after positive meeting of FDA panel on sickle-cell disease therapyMarket Watch • 11/01/23
FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up studyReuters • 10/31/23
CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell DiseaseGlobeNewsWire • 10/31/23
Will CRISPR Therapeutics AG (CRSP) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 10/31/23
CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)GlobeNewsWire • 10/31/23
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain PatientThe Motley Fool • 10/30/23
CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene TherapyInvestorPlace • 10/27/23
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over TimeThe Motley Fool • 10/21/23
Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A BuySeeking Alpha • 10/13/23
Cathie Wood Is Buying CRISPR Therapeutics Ahead of This Big Event. Should You?The Motley Fool • 10/10/23
2 Growth Stocks That Can Rocket 98% to 108% Higher, According to Wall StreetThe Motley Fool • 10/05/23
Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors RichInvestorPlace • 10/03/23